<DOC>
	<DOCNO>NCT02224742</DOCNO>
	<brief_summary>Diabetic foot ulcer source considerable suffer cost currently wind care product available demonstrated improve healing , cost effective . There however small number study examine use platelet fluid derive platelet , either patient 's blood blood bank product . These suggest promise , suffer technical difficulty make suitable wound care product volume blood require derive product . It think reason may work growth factor release platelet may stimulate wound heal . This study formal , randomise control trial ass new device create wound care product plug patch comprise fibrin , white cell platelet derive 18 ml patient blood . The application fibrin/white cell/platelet patch patient wound weekly basis compare usual best care patient hard heal Diabetic Foot Ulcers secondary care set 25 centre United Kingdom , Denmark Sweden .</brief_summary>
	<brief_title>LeucoPatch Management Hard-to-heal Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>People age 18 year diabetes complicate one ulcer foot foot level malleoli , exclude ulcer confine interdigital cleft . Those one eligible ulcer one usually large clinically significant select screen index ulcer . Eligible ulcer hardtoheal , mean crosssectional area decrease le 50 % four week runin period . HbA1c ≤108 mmol/mol screen The crosssectional area index ulcer ≥50 ≤1000 mm2 end 4 week runin period . The index ulcer clinically noninfected accord IDSA criterion Either anklebrachial index ( ABPI ) affect limb 0.50 1.40 dorsalis pedis pulse and/or tibialis posterior pulse palpable . Participants capacity understand study procedure , able provide write informed consent . Haemoglobin concentration &lt; 105 g/L 6.5 mmol/L screening . Presence sicklecell anaemia , haemophilia , thrombocytopenia ( &lt; 100x109/L ) clinically significant blood dyscrasia Known potential infectivity blood product , include know HIV hepatitis Dialysis estimate GFR ( base cystatine C serum creatinine ) &lt; 20 ml/min/1.73m2 Increase crosssectional area index ulcer ≥25 % 4 week runin period , either small 50 mm2 large 1000 mm2 end time Revascularisation procedure affect limb plan , undertake within 4 week prior screen Current treatment cytotoxic drug systemically administer glucocorticoid Treatment foot ulcer growth factor , stem cell equivalent preparation within 8 week prior screen Likely inability comply need weekly visit plan activity Participation another interventional clinical foot ulcerhealing trial within 4 week prior screen Prior enrollment trial Judgement investigator patient capacity understand study procedure provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>